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Abstract
Background: Inflammation has been proposed to be important in the pathogenesis of diabetic retinopathy. An early feature
of inflammation is the release of cytokines leading to increased expression of endothelial activation markers such as vascular
cellular adhesion molecule-1 (VCAM-1). Here we investigated the impact of diabetes and dyslipidemia on VCAM-1
expression in mouse retinal vessels, as well as the potential role of tumor necrosis factor-a (TNFa).
Methodology/Principal Findings: Expression of VCAM-1 was examined by confocal immunofluorescence microscopy in
vessels of wild type (wt), hyperlipidemic (ApoE2/2) and TNFa deficient (TNFa2/2, ApoE2/2/TNFa2/2) mice. Eight weeks of
streptozotocin-induced diabetes resulted in increased VCAM-1 in wt mice, predominantly in small vessels (,10 mm).
Diabetic wt mice had higher total retinal TNFa, IL-6 and IL-1b mRNA than controls; as well as higher soluble VCAM-1 (sVCAM-
1) in plasma. Lack of TNFa increased higher basal VCAM-1 protein and sVCAM-1, but failed to up-regulate IL-6 and IL-1b
mRNA and VCAM-1 protein in response to diabetes. Basal VCAM-1 expression was higher in ApoE2/2 than in wt mice and
both VCAM-1 mRNA and protein levels were further increased by high fat diet. These changes correlated to plasma
cholesterol, LDL- and HDL-cholesterol, but not to triglycerides levels. Diabetes, despite further increasing plasma cholesterol
in ApoE2/2 mice, had no effects on VCAM-1 protein expression or on sVCAM-1. However, it increased ICAM-1 mRNA
expression in retinal vessels, which correlated to plasma triglycerides.
Conclusions/Significance: Hyperglycemia triggers an inflammatory response in the retina of normolipidemic mice and up-
regulation of VCAM-1 in retinal vessels. Hypercholesterolemia effectively promotes VCAM-1 expression without evident
stimulation of inflammation. Diabetes-induced endothelial activation in ApoE2/2 mice seems driven by elevated plasma
triglycerides but not by cholesterol. Results also suggest a complex role for TNFa in the regulation of VCAM-1 expression,
being protective under basal conditions but pro-inflammatory in response to diabetes.
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Introduction
The pathogenesis of diabetic retinopathy has lately been
recognized to involve low-grade, chronic inflammation[1,2,3],
proposed to be the result of persistent hyperglycemia as well as of
dyslipidemia[1,4,5]. Up-regulation of inflammatory mediators
and adhesion molecules are early features of diabetic retinopa-
thy[6], leading to accumulation of leukocytes, altered vessel
reactivity and subsequent activation of receptors and transcrip-
tion factors, ultimately resulting in apoptosis or proliferation of
various cell types in the retina[5,7], e.g., loss of pericytes and
proliferation of endothelial cells. However, it is still a matter of
debate whether the inflammatory response is a local phenomenon
or not, since clinical studies show variable associations between
markers of systemic inflammation and risk of diabetic retinop-
athy[8,9,10].
Endothelial cells release multiple inflammatory mediators and
express various adhesion molecules such as intercellular and
vascular cellular adhesion molecules (ICAM-1, VCAM-1), P- and
E-selectins[4]. These are membrane proteins necessary for
anchoring leukocytes to the vessel wall and are well established
markers of endothelial dysfunction in inflammatory conditions
such as atherosclerosis[7,11,12]. Soluble forms of these adhesion
molecules and selectins have been demonstrated in serum of
diabetic patients, suggesting that they may play a role in diabetic
endothelial activation[6,13,14]. Moreover, increased levels of
soluble (s)VCAM-1 have been demonstrated in the vitreous of
diabetic patients[15,16,17,18]. In type 2 diabetic subjects (T2D),
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serum levels of sVCAM-1 and sE-selectin are increased both in
patients with micro- and macrovascular complications, whereas
sICAM-1 levels are higher only in the microvascular group[19].
This suggests potential differential regulation of adhesion mole-
cules and maybe also differential functions. In line with this idea,
recent studies have shown associations between sVCAM-1 in
human serum and proliferative diabetic retinopathy, but not for
sICAM-1[20][8]. ICAM-1 has been widely used as a marker of
endothelial activation in experimental studies of diabetic retinop-
athy, but much less is known about VCAM-1 in this context.
Accordingly, the first aim of the present study was to evaluate
potential changes in VCAM-1 expression in a streptozotocin
(STZ) model of diabetes in mouse.
Dyslipidemia is a well established proinflammatory agent in
large arterial vessel disease[21] and could be of importance in the
pathogenesis of microvascular complications of diabetes[22]. In
the Diabetes Control and Complications Trial (DCCT)[23], it was
shown that severity of retinopathy was associated with increasing
serum triglycerides and inversely associated with HDL-cholesterol
levels[24]. There is also evidence for the involvement of
hypercholesterolemia in the formation of hard exudates in diabetic
retina, with potential negative effects on disease progression[25].
Lipid-modifying fenofibrate has been shown to reduce the need for
laser treatment of sight-threatening diabetic retinopathy, but the
effect did not seem to be attributable to changes in lipid
profile[26]. Furthermore, results from the ACCORD Study
Group and ACCORD Eye Study Group showed that combina-
tion therapy (simvastatin plus fenofibrate) reduced the rate of
progression of diabetic retinopathy[27]. Despite accumulating
clinical evidence, the underlying mechanisms of lipid involvement
are not clear and experimental data are sparse. In the present
study, we used the genetically modified apolipoprotein E deficient
(ApoE2/2) mouse, a widely used mouse model of atherosclerosis
and natural hypercholesterolemia, to study the effect of dyslipide-
mia on endothelial VCAM-1 expression. ApoE is a structural
component of astrocytes in the central nervous system and of
Mu¨ller cells in the retina, and it has important lipid transport
regulatory and immunologic functions[28]. In ophthalmology, the
ApoE2/2 model is most frequently used in neovascular age-
related macular degeneration (AMD) experiments, but is not as
widely used for studies of diabetic retinopathy. Although the lipid
profile of the ApoE2/2 differs somehow from that of dyslipidemic
human subjects, we suggest that this model may be relevant for
addressing the issue of inflammation and/or endothelial activation
in diabetic retinopathy. The second aim of our study was thus to
assess whether the VCAM-1 expression pattern in retinal vessels
was different in dyslipidemic compared to wild type (wt) mouse,
and how diabetes would influence such an expression. As a
complement to genetically caused dyslipidemia, we also explored
the effects of high fat diet on VCAM-1 expression in retinal vessels.
There is strong evidence that tumor necrosis factor-a (TNFa) is
involved in inflammatory processes in diabetic retinopathy[4,29].
TNFa is one of the key cytokines in inflammation, but the
pathways directly or indirectly activated upon TNFa engagement
may vary widely and lead to different outcomes depending on cell-
and receptor type as well as on environmental factors[30]. Both
inflammatory and anti-inflammatory TNFa actions have been
described[31,32]. The third aim of the present study was to
evaluate the influence of TNFa on endothelial VCAM-1
expression in diabetes and/or dyslipidemia, using TNFa knockout
mice.
Results
Effect of diabetes and high fat diet on body weight,
blood glucose, triglycerides and cholesterol
To investigate the effects of diabetes on VCAM-1 expression, as
well as the potential role of TNFa, C57BL/6 wild-type (wt),
ApoE2/2, TNFa2/2 and ApoE2/2/TNFa2/2 mice were chow-
fed until 22 weeks of age, injected with STZ or vehicle once a day
for 5 days and kept on chow diet for additional 8 weeks. Mean
body weight, blood glucose, plasma triglycerides, total cholesterol
as well as LDL- and HDL-cholesterol for the different genotypes
are listed in Table 1. STZ treatment significantly increased blood
Table 1. Body weight, blood glucose, triglycerides, total cholesterol, LDL and HDL in control and diabetic mice of different
genotypes (experimental set 1).
Genotype
Body
weight (g)
Blood glucose
(mmol/l)
Triglycerides
(mmol/l)
Total cholesterol
(mmol/l)
HDL cholesterol
(mmol/l)
LDL cholesterol
(mmol/l)
wt control (n = 12) 23.461.5 7.160.6 0.3960.09 1.3460.19 0.7860.28 0.4360.23
wt diabetes (n = 16) 20.561.9 *** 16.965.9 *** 0.5560.15 1.7060.31 1.0260.42 0.4960.36
ApoE2/2 control (n = 24) 23.662.4 8.860.8 0.6260.17# 9.0862.09### 0.5160.20 7.1762.05###
ApoE2/2 diabetes (n = 29) 21.361.8 *** 18.665.4 *** 0.8960.36 *** 14.1064.97 *** 0.4160.11 12.4165.14 ***
TNF-a2/2 control (n = 10) 23.461.0 7.161.0 0.4460.10 1.5460.29
TNF-a2/2 diabetes (n = 14) 20.660.5 ** 14.464.3 *** 0.4160.16 2.1760.53
ApoE2/2/TNF-a2/2 control
(n = 15)
22.761.1 7.761.0 0.5760.12 9.7861.88
ApoE2/2/TNF-a2/2 diabetes
(n = 15)
20.062.7 *** 21.065.9 *** 0.7260.23 20.3465.04 ***
Values represent mean 6 SD. HDL, high density lipoprotein; LDL, low density lipoprotein. Blood glucose represents average blood glucose values during the
experiments (from week 2 until termination). Body weight and lipids express values measured at the end of the experiments. Two HDL-cholesterol measurements in the
‘‘wt diabetes’’ group yielded higher than total cholesterol values, and were therefore excluded from calculations. Missing values are due to limited plasma availability.
Two-way analyses of variance (for the effects of diabetes and genotype) revealed no interactions between factors. Bonferroni posttests yielded
**p,0.01,
***p,0.001 for comparisons between control and diabetes of the same genotype;
#p,0.05 and
###p,0.001 vs. wt control.
doi:10.1371/journal.pone.0012699.t001
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glucose values by at least 2-fold in all groups. At the time mice
were euthanized, diabetic mice had lower body weight than non-
diabetic littermates. As expected, ApoE2/2 mice had higher
plasma triglycerides, total cholesterol and LDL-cholesterol than wt
mice and as also described by others[33,34], all three parameters
were further increased in diabetic ApoE2/2 mice. In ApoE2/2
mice also deficient for TNFa, cholesterol levels were also increased
by diabetes and this effect was more pronounced than in ApoE2/2
mice. Hence, diabetic ApoE2/2 and ApoE2/2/TNFa2/2 mice
had both hyperglycemia and hyperlipidemia, whereas wt and
TNFa2/2 mice exhibited hyperglycemia but no significant
changes in plasma lipids.
To further elucidate the impact of hyperlipidemia on endothe-
lial activation, two separate sets of experiments were performed, a
first one in which hyperlipidemic ApoE2/2 mice were fed a high
fat diet (HFD) for 4 weeks and a second one in which
normolipidemic mice were fed a HFD for 4 or 8 weeks. Mean
body weight, blood glucose and plasma lipids for these
experiments are summarized in Tables 2 and 3.
Effect of diabetes on VCAM-1 protein expression in
retinal vessels
To determine the effect of diabetes on endothelial activation in
retinal arteries, we measured VCAM-1 expression by confocal
immunofluorescence microscopy. As previously shown by us[35]
and others[36], VCAM-1 was detected in both endothelial and
smooth muscle cells in arteries from mouse, with higher expression
in endothelial cells. As shown in Figure 1, when non-diabetic
mice of different genotypes were compared, ApoE2/2 mice were
found to express higher VCAM-1 levels than wt mice (p,0.05),
suggesting that hyperlipidemia may induce VCAM-1 expression in
retinal vessels. Interestingly, TNFa deficient mice also expressed
higher VCAM-1 levels than wt mice (p,0.001) and TNFa
deficient ApoE2/2 mice exhibited higher VCAM-1 expression
than ApoE2/2 mice (p,0.001), suggesting that TNFa may be
involved in the regulation of basal VCAM-1 expression.
When the effect of diabetes was evaluated (Figure 1), VCAM-1
expression was found to be increased in wt mice (p,0.001), but no
effects were demonstrated in hyperlipidemic ApoE2/2 mice.
VCAM-1 expression was even decreased in diabetic TNFa2/2
mice when compared to non-diabetic mice of the same genotype
(p,0.001). The level of VCAM-1 expression correlated to the
vessel diameter, with higher expression in larger vessels.
Correlations were significant for all genotypes (r=0.264 and
r=0.616 for wt and TNFa2/2 mice, respectively; p,0.001), with
weaker correlations for ApoE2/2 and ApoE2/2/TNFa2/2 mice
(r=0.124 and r=0.123, respectively; p,0.01). When vessels were
divided in quartiles according to vessel diameter (,10 mm, 10–
15 mm, 16–23 mm and .23 mm; Figure 2), it became evident
that the overall effect of diabetes on VCAM-1 expression in wt
mice was predominantly driven by changes in the very small
vessels (,10 mm), whereas the overall effect observed in TNFa2/2
mice was predominantly driven by changes in the larger vessels
(.23 mm).
Within the same retina, not all arteries expressed VCAM-1
protein. To assess whether genotype or diabetes had any impact
on the pattern of VCAM-1 expression, the number of VCAM-1
positive vessels in each retina was calculated as percentage of total
number of vessels. A vessel was considered positive if mean
VCAM-1 intensity was higher than mean background intensity,
whereas it was considered negative if mean VCAM-1 intensity was
below. The average background intensity did not differ between
genotypes. The percentage of VCAM-1 positive vessels in wt and
ApoE2/2 mice was lower in diabetic animals (p,0.05 and
Table 2. Body weight, blood glucose, triglycerides, total cholesterol, LDL and HDL in wt and ApoE2/2 mice, fed normal chow or
HFD (experimental set 2).
Genotype
Body
weight (g)
Blood glucose
(mmol/l)
Triglycerides
(mmol/l)
Total cholesterol
(mmol/l)
HDL cholesterol
(mmol/l)
LDL cholesterol
(mmol/l)
wt chow diet (n = 7) 24.064.9 9.362.9 0.6360.41 1.7660.48 0.7160.23 0.7660.35
ApoE2/2 chow diet (n = 5) 23.661.7 9.460.6 0.4760.11 10.3565.19 ** 0.2060.08 *** 6.7761.10 **
ApoE2/2 HFD (n = 5) 22.561.0 8.160.8 0.6260.12 8.8164.72 * 0.2760.12 ** 13.1165.48 ***#
Values represent mean 6 SD. HFD, high fat diet; HDL, high density lipoprotein; LDL, low density lipoprotein. HDL/LDL data are missing for one of the ApoE2/2 animals
fed with HFD, since the HDL value was below detection limit. One-way analyses of variance followed by Bonferroni tests were performed;
*p,0.05,
**p,0.01,
***p,0.001 vs. wt chow diet;
#p,0.05 vs. ApoE2/2 chow diet.
doi:10.1371/journal.pone.0012699.t002
Table 3. Body weight, blood glucose, triglycerides and total cholesterol in FVBN mice, fed normal chow or HFD for 4 or 8 weeks
(experimental set 3).
Genotype Body weight (g) Blood glucose (mmol/l) Triglycerides (mmol/l) Total cholesterol (mmol/l)
FVBN chow diet (n = 16) 34.964.7 9.561.1 1.2360.47 3.3360.52
FVBN HFD 4 weeks (n = 5) 40.866.2 12.663.4 * 0.6560.22 * 5.1761.44 ***
FVBN HFD 8 weeks (n = 8) 41.867.2 * 11.362.6 0.9560.45 5.9560.95 ***
Values represent mean 6 SD. HFD, high fat diet. One-way analyses of variance followed by Bonferroni tests were performed;
*p,0.05,
***p,0.001 vs. wt chow diet.
doi:10.1371/journal.pone.0012699.t003
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p,0.001, respectively), whereas no differences were observed in
the TNFa deficient genotypes (Figure S1).
Effect of diabetes on endothelial activation
As a complementary approach to evaluate a potential
endothelial dysfunction in response to diabetes, the expression of
VCAM-1, ICAM-1, P-selectin and E-selectin mRNA was measured in
intact retinas of wt, ApoE2/2, TNFa2/2 and ApoE2/2/TNFa2/
2 mice by real time RT-PCR. As opposed to what we found when
VCAM-1 protein was measured in retinal arteries by confocal
microscopy (see Figure 1), no differences in VCAM-1 mRNA
expression were observed between genotypes or in response to
diabetes when whole retinas were examined (Figure 3A). For the
other adhesion molecules ICAM-1, P-selectin and E-selectin, mRNA
levels were higher in diabetic wt mice compared to non-diabetic
controls of the same genotype, but differences did not reach
statistical significance. Lack of ApoE or TNFa had no impact on
basal expression of these adhesion molecules. Further, diabetes
had no effect on the mRNA levels of any of these targets in ApoE
or TNFa deficient mice (Figure 3A). However, when mRNA
levels of VCAM-1, ICAM-1 and E-selectin were studied in isolated
retinal vessels from ApoE2/2 using the same assays as for intact
Figure 1. Effects of diabetes on VCAM-1 protein expression in retinal vessels. (A) Confocal immunofluorescence microscopy images
showing VCAM-1 staining (red) in retinal whole-mounts from control non-diabetic and diabetic wild type (wt), ApoE2/2, TNFa2/2 and ApoE2/2/
TNFa2/2 mice. The DNA-binding dye SYTOX (green) was used for nuclear localization. Bars = 50 mm. Measurements were performed 8 weeks after the
first STZ-injection, when mice were 30 weeks of age. (B) Summarized data from experiments in A showing mean fluorescence intensity of VCAM-1 in
the different groups. White bars represent control and black bars diabetic mice. Two-way analysis of variance (for the effects of diabetes and
genotype) revealed significant interactions between factors. Bonferroni posttests yielded *p,0.05 and ***p,0.001 for comparisons between
ApoE2/2 and TNFa2/2, respectively vs. wt control; ***p,0.001 for comparison between ApoE2/2 and ApoE2/2/TNFa2/2; and ###p,0.001 for
comparisons between control and diabetes of the same genotype.
doi:10.1371/journal.pone.0012699.g001
VCAM-1 in Mouse Retina
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retina, a clear increase of ICAM-1 in response to diabetes was
observed (p,0.05) and similar trends were seen for VCAM-1 and
E-selectin (n.s.; Figure 3B). Even though blood glucose, plasma
triglycerides and total cholesterol were all significantly increased
by diabetes, expression of endothelial adhesion molecules
correlated only to triglyceride levels. Correlation parameters were
r=0.429 for VCAM-1 (p,0.05), r=0.441 for ICAM-1 (p,0.05) and
r=0.480 for E-selectin (p,0.05). These results underscore the
importance of measuring expression of vascular endothelial
markers on isolated vessels and the limited resolution of expression
measurements in whole retina homogenates.
For a more systemic indication of endothelial activation in
response to diabetes, we measured soluble VCAM-1 (sVCAM-1)
in plasma from wt, ApoE2/2 and ApoE2/2/TNFa2/2 mice. As
shown in Figure 3C, differences in sVCAM-1 resemble the
pattern of expression of VCAM-1 protein observed in retinal
vessels by confocal microscopy (see Figure 1). TNFa deficient
ApoE2/2 mice exhibited higher sVCAM-1 levels than ApoE2/2
mice (p,0.001), again supporting a role for TNFa in the
regulation of basal VCAM-1 expression. Also, sVCAM-1 levels
were increased in wt mice in response to diabetes (p,0.05), but no
effect was observed in hyperlipidemic ApoE2/2mice (Figure 3C).
The effect of diabetes on the expression of various inflammatory
(TNFa, IL-6, IL-1b and IFNc) and apoptosis markers (caspase-1)
was also evaluated in intact retinas from wt, ApoE2/2, TNFa2/2
and ApoE2/2/TNFa2/2 mice. In wt mice, diabetes resulted in a
clear increase in TNFa, IL-6 and IL-1b mRNA expression levels
(p,0.01, p,0.01 and p,0.05, respectively) and in a tendency to
higher IFNc and caspase-1 mRNA levels (n.s.; Figure 4). No
significant changes were detected in retinas of ApoE or TNFa
deficient mice in response to diabetes. When expression levels
were compared among mice of different genotypes, lack of TNFa
mRNA was confirmed in TNFa2/2 and ApoE2/2/TNFa2/2
animals, but no significant differences in the basal levels of the
other studied targets could be dissected using RNA from whole
retinas (Figure 4).
Effect of hyperlipidemia on VCAM-1 expression in retinal
vessels
As shown in Figure 1, VCAM-1 protein expression was
significantly higher in ApoE2/2 than in wt mice when measured
at 30 weeks of age. To further elucidate the effect of
hyperlipidemia on VCAM-1 expression, we compared expression
levels in wt and ApoE2/2 mice fed regular chow or high fat diet
(HFD), this time at an earlier age of 17 weeks. Confocal
immunofluorescence experiments revealed that VCAM-1 protein
levels were elevated in the retinal vessels of ApoE2/2 mice when
compared to wt mice and that expression was further enhanced by
HFD (Figures 5A and B). As predicted, ApoE2/2 mice had
higher levels of total cholesterol than wt mice (p,0.01); elevated
LDL-cholesterol and decreased HDL-cholesterol (p,0.01 and
p,0.001, respectively; Table 2). HFD further increased the levels
of LDL-cholesterol in ApoE2/2 mice (p,0.05). A positive
Figure 2. The effect of diabetes on VCAM-1 expression is dependent on retinal vessel size. Summarized data from confocal
immunofluorescence microscopy experiments showing mean fluorescence intensity of VCAM-1 in retinal vessels divided into quartiles depending on
vessel diameter (,10 mm, 10–15 mm, 16–23 mm and .23 mm). Each graph represents the expression-diameter relationship in the different
genotypes. White bars are for control and grey bars for diabetes. The two first bars in each graph (in white and black, for control and diabetes
respectively) show the same data as in Figure 1, but are displayed here as references. *p,0.05 and ***p,0.001 indicate differences between control
and diabetes of the same size and genotype.
doi:10.1371/journal.pone.0012699.g002
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Figure 3. Changes in the expression of vascular adhesion markers in retinal vessels are difficult to resolve if measured in total
retinal RNA. (A) Expression of VCAM-1, ICAM-1, P- and E-selectin mRNA was measured by real time RT-PCR in intact retinas of control (white bars) and
diabetic (black bars) wt, ApoE2/2, TNFa2/2 and ApoE2/2/TNFa2/2 mice. No statistically significant differences were seen between genotypes or
between retinas from control and diabetic mice.Results are normalized to the expression of the housekeeping control cyclophilin B. (B) VCAM-1,
ICAM-1 and E-selectin mRNA were measured in isolated retinal vessels from control (white) and diabetic (black) ApoE2/2 mice. Values are normalized
to the expression of cyclophilin B and GAPDH. *p,0.05 indicates difference to the control group. (C) Mean sVCAM-1 concentrations in plasma (ng/
ml), measured by ELISA are depicted for control (white bars) and diabetic (black bars) wt, ApoE2/2 and ApoE2/2/TNFa2/2 mice. *p,0.05 vs. wt
control and ***p,0.001 for differences between non-diabetic ApoE2/2 and ApoE2/2/TNFa2/2 mice. For A–C, measurements were performed 8
weeks after the first STZ-injection, when mice were 30 weeks of age.
doi:10.1371/journal.pone.0012699.g003
VCAM-1 in Mouse Retina
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correlation was found between VCAM-1 expression and choles-
terol (r=0.806, p,0.001) and LDL-cholesterol (r=0.796,
p,0.001), whereas VCAM-1 correlated negatively to HDL-
cholesterol (r=20.756, p,0.001). VCAM-1 expression did not
correlate to plasma triglycerides. In agreement with measurements
of sVCAM-1 in plasma from wt and ApoE2/2 mice at 30 weeks of
age (Figure 3C), no differences in sVCAM-1 concentrations were
found between wt and ApoE2/2 mice at 17 weeks of age, but
elevated sVCAM-1 was measured in aged-matched ApoE2/2
mice fed HFD for 4 weeks (Figure 5C).
In a separate set of experiments, we investigated whether
VCAM-1 expression was affected by HFD in normolipidemic
mice (ApoE competent). Indeed, VCAM-1 mRNA measured in
isolated retinal vessels revealed higher expression of this adhesion
molecule after 8 weeks of HFD (p,0.05) and a less pronounced
effect after 4 weeks of HFD (Figure 5D). After 4 weeks of HFD,
elevated blood glucose (p,0.05) and decreased plasma triglycer-
ides (p,0.05) were observed. Plasma cholesterol was higher both
after 4 and 8 weeks of HFD (p,0.001, table 3). Despite changes
in blood glucose and triglycerides, VCAM-1 mRNA expression
correlated only to total plasma cholesterol (r=0.428, p,0.05). As
for ApoE2/2 mice (Figure 5C), levels of sVCAM-1 were
increased both after 4 and 8 weeks of HFD in these mice
(Figure 5D). Taken together, these results demonstrate that even
moderate changes in plasma cholesterol as those observed in
normolipidemic FVBN mice after HFD, are able to drive VCAM-1
mRNA expression in retinal vessels and are also translated into
elevated sVCAM-1 protein in plasma. Interestingly, ICAM-1 and
E-selectin mRNA were not affected by HFD (Figure S2). No gross
morphological changes as assessed by hematoxylin staining were
observed in retinal sections of dyslipidemic mice when compared
to normolipidemic mice (data not shown).
Discussion
The present study investigated early retinal endothelial activation
in diabetes and/or dyslipidemia by assessment of VCAM-1
expression in mouse retinal vessels, as well as the potential role of
TNFa. Our major findings are as follows: (1) VCAM-1 protein
levels were increased in retinal vessels of wt mice after 8 weeks of
diabetes, at a time-point when the expression of the inflammatory
cytokines TNFa, IL-6 and IL-1b was elevated in retina and levels of
sVCAM-1 in plasma were higher; (2) TNFa2/2 deficient mice
exhibited higher basal levels of VCAM-1 protein in retinal vessels
and sVCAM-1 in plasma than wt mice, but failed to up-regulate
IL-6 and IL-1b mRNA and VCAM-1 protein in response to
diabetes. (3) Basal VCAM-1 protein expression in retinal vessels was
higher in hyperlipidemic ApoE2/2 than in normolipidemic wt mice
and both VCAM-1mRNA and protein levels were further increased
by high fat diet, probably driven by changes in plasma cholesterol,
LDL- and HDL-cholesterol, but not in triglycerides; (4) Diabetes
had no effects on VCAM-1 protein expression or on plasma
sVCAM-1 levels in ApoE2/2mice, but it increased ICAM-1mRNA
expression in retinal vessels, apparently driven by changes in plasma
triglycerides independently of plasma cholesterol.
Our results in wt mice show that STZ-induced hyperglycemia
results in enhanced endothelial activation in mouse retinal
vessels, as assessed by measurements of VCAM-1 protein
expression. This is in line with the proposed mechanism
underlying the pathogenesis of diabetic retinopathy, namely
that hyperglycemia through various pathways (including accu-
mulation of sorbitol and advanced glycation end-products,
oxidative stress, up-regulation of the renin-angiotensisn system
and vascular endothelial growth factor) initiates a cascade of
events leading to retinal vascular endothelial dysfunction[37].
Figure 4. Diabetes enhances the expression of inflammatory cytokines in the retina of wt mice but not of ApoE- or TNFa deficient
mice. Expression of TNFa, IL-6, IL-1b, IFNc and caspase-1 mRNA was measured by real time RT-PCR in intact retinas of control (white bars) and diabetic
(black bars) wt, ApoE2/2, TNFa2/2 and ApoE2/2/TNFa2/2 mice. Values are normalized to the expression of cyclophilin B. *p,0.05 and **p,0.01
indicates differences to control wt mice.
doi:10.1371/journal.pone.0012699.g004
VCAM-1 in Mouse Retina
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As we demonstrated in a previous study in cerebral arteries[35],
VCAM-1 is not only confined to the endothelium, but it is also
expressed in smooth muscle cells surrounding the larger arteries
of the retina. The fact that the effect of diabetes on VCAM-1
was predominant in small caliber vessels (,10 mm) is interesting
considering that capillary degeneration begins early in diabetes
retinopathy and as it advances, contributes to the large non-
perfused areas of the retina.
In the retinas of diabetic wt mice, we also found significantly
increased levels of TNFa, IL-6 and IL-1b mRNA expression and a
tendency to increased IFNc and caspase-1 mRNA, indicating some
degree of local inflammation after 8 weeks of diabetes. Plasma
levels of these pro-inflammatory cytokines have been suggested as
potential biomarkers associated with hyperglycemia and diabetes
comorbidities, of value for prediction of diabetes complications[6].
Local elevation of these cytokines in diabetes has indirectly been
demonstrated from measurements in the vitreous of pa-
tients[38,39,40]. Direct experimental evidence in mice models of
diabetes is limited, with a study demonstrating elevation of TNFa
mRNA in male C57Bl6 mice 5 months after induction of diabetes
by STZ[41] and another study showing activation of caspase-1/
IL-1b signaling in retinas of diabetic mice[42]. Evidence for local
Figure 5. High fat diet (HFD) increases VCAM-1 expression in retinal vessels. (A) Confocal immunofluorescence microscopy images
showing VCAM-1 expression (red) and nuclei stained by SYTOX (green) in retinal whole-mounts from wt mice fed normal chow diet and from
ApoE2/2 mice fed normal chow or 4 weeks of HFD. Bars = 50 mm. Measurements were performed when mice were 17 weeks of age. (B) Summarized
data from experiments as in A, showing increased mean fluorescence intensity of VCAM-1 in ApoE2/2 (light gray bar) when compared to wt controls
(white bar; ***p,0.001) and further increased VCAM-1 expression in response to HFD (dark gray bar; ##p,0.01). (C) Mean sVCAM-1 concentrations in
plasma from the same mice used in A and B. ***p,0.001 vs. wt chow and #p,0.05 for differences between ApoE2/2 groups (chow vs. HFD). (D)
Expression of VCAM-1 mRNA was studied by real time RT-PCR in normolipidemic FVBN mice. Expression was enhanced by 4 or 8 weeks of HFD (plain
and patterned gray bars, respectively) when compared to mice fed regular chow diet (white bars). The effects were significant after 8 weeks
(*p,0.05). Values are normalized to the expression of cyclophilin B and GAPDH. (E) Mean sVCAM-1 concentrations in plasma from the same mice
used in D. **p,0.01 vs. wt chow.
doi:10.1371/journal.pone.0012699.g005
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up-regulation of IL-6 and IFNc in retina in diabetes comes from
studies in rats[43,44]. In our hands, diabetic wt mice exhibited
higher plasma sVCAM-1, suggesting not only up-regulation of
inflammatory mediators in the retina, but also a more systemic
endothelial activation in this model.
Another finding in our study was that basal VCAM-1 protein
expression in retinal vessels was elevated in ApoE2/2 mice
compared to wt mice, the difference being more pronounced in
younger mice (30 vs. 17 weeks of age), and further elevated by
HFD. Induction of VCAM-1 expression by HFD was clear both in
normolipidemic FVBN mice after 8 weeks of diet and in
hyperlipidemic ApoE2/2 already after 4 weeks of diet. One
explanation for these differences in basal- and diet-induced
VCAM-1 expression could be the differences in plasma choles-
terol, HDL- and LDL-cholesterol between genotypes, since these
parameters seem to correlate well with VCAM-1 levels in retinal
vessels. This cholesterol-sensitivity of VCAM-1 expression we
show in retinal vessels is consistent with features of VCAM-1
described in the context of atherosclerosis, where endothelial cells
express VCAM-1 in response to cholesterol feeding selectively in
areas prone to lesion formation and before leukocyte recruitment
begins[11]. Of interest to note is that this cholesterol-sensitivity of
VCAM-1 was not shared by ICAM-1 or E-selectin, since at least in
our models, HFD had no significant effects on the expression of
these adhesion molecules. In the vessel wall, the mechanism of
VCAM-1 induction by HFD seems to be dependent on
inflammation, initiated by modified lipoprotein particles such as
oxidized phospholipids and short-chain aldehydes, which in turn
activate VCAM-1 transcription via activation of NF-kB[45].
Interestingly, TNFa and IL-1b have also been shown to induce
VCAM-1 expression by this pathway[11] and may account in the
absence of hyperlipidemia but under hyperglycemic conditions
(such as in the diabetic wt mice in this study), for the observed up-
regulation of VCAM-1 in retinal vessels.
Long-term effects of dyslipidemia may be of importance for
progression of diabetic retinopathy, as shown by Barile et al.[46],
who demonstrated accelerated signs of diabetic retinopathy in
hyperglycemic-hyperlipidemic ApoE2/2 db/db mice at 6 months
of age compared to hyperglycemic-normolipidemic mice. They
show that the aggravation of diabetic retinopathy was associated
with an increased activation of the advanced glycation end-
product and its receptor (AGE/RAGE). Activation of the AGE/
RAGE axis has been demonstrated to correlate with increased
inflammation and leukocyte recruitment as well as TNFa
activity[47], and would provide an alternative link between
dyslipidemia, endothelial activation/inflammation and diabetic
retinopathy.
Another conclusion from the present study is that measurements
of vascular endothelial markers by RT-PCR using total retinal
RNA have limited resolution and are not sensitive enough to
dissect e.g. the effects of diabetes or genotype on VCAM-1
expression. Instead, other methods such as confocal microscopy
for spatial resolution of VCAM-1 protein and/or RT-PCR for
VCAM-1 mRNA using RNA from isolated retinal vascular
networks seem more appropriate. This is best illustrated by the
lack of significant differences in the expression of VCAM-1, ICAM-
1 and E-selectin mRNA in ApoE2/2 mice in response to diabetes
when whole retinas were examined, as opposed to a clear increase
of ICAM-1 in response to diabetes when expression was examined
in isolated vessels. This diabetes-induced ICAM-1 expression in
ApoE2/2 mice was not accompanied by increased levels of pro-
inflammatory cytokines in retina, nor with elevated sVCAM levels,
suggesting a different scenario than that found in diabetic wt mice.
Further, ICAM-1 mRNA expression correlated to plasma
triglyceride but not to cholesterol levels. Collectively, it seems
that diet-induced VCAM-1 expression may be driven by serum
cholesterol, whereas diabetes-induced ICAM-1 expression may be
driven by triglycerides in ApoE2/2 mice, by a mechanism yet to
be described. Our data also highlights potential differential
regulation of adhesion molecules in retinal vessels.
TNFa is a multifunctional cytokine with important roles in
inflammation and apoptosis, but also able to exert anti-
inflammatory and protective actions[30,32], depending on
receptor type and cellular and environmental status. TNFa has
been proposed as a link between metabolic dysregulation and
inflammation and/or vascular dysfunction in diabetes[47,48], and
it is well established as a key molecule in diabetic retinopathy[1].
In the present study we found that TNFa2/2 deficient mice
exhibited higher basal levels of VCAM-1 protein in retinal vessels
and sVCAM-1 in plasma than wt mice, but these mice failed to
up-regulate IL-6 and IL-1b mRNA and VCAM-1 protein in
response to diabetes. These results suggest a dual role for TNFa in
the regulation of VCAM-1 expression in retinal vessels, being
protective under basal conditions but promoting endothelial
activation in response to diabetes. Further, lack of TNFa
prevented the up-regulation of IL-6 and IL-1b mRNA otherwise
observed in wt mice in response to diabetes. This absence of
inflammatory component in the hyperglycemic situation may be
the reason why VCAM-1 expression is not increased in the retinal
vessels of diabetic TNFa2/2 mice. In line with this idea, recent in
vitro studies using human endothelial cells, demonstrated that
hyperglycemia alone was not sufficient to induce expression of
VCAM-1, but it significantly enhanced the induction of endothe-
lial VCAM-1 elicited by IL-1b[49]. Results from experiments
using TNFa deficient mice should be interpreted with caution,
since we cannot exclude a generalized defect in the immune
system[31,32,50]. However, results from studies using the TNFa
inhibitor etanercept on diabetic rats or TNF receptor deficient
mice, recently provided strong evidence for the role of TNFa as a
promoter of retinal dysfunction in diabetes[51].
In summary, STZ-induced hyperglycemia triggers an inflam-
matory response in the retina of normolipidemic mice and
concomitant up-regulation of VCAM-1 in retinal vessels. Hyper-
cholesterolemia effectively promotes VCAM-1 expression without
evident stimulation of inflammation. Diabetes-induced endothelial
activation in ApoE2/2 mice seems driven by elevated plasma
triglycerides and not by cholesterol. Results also suggest a complex
role for TNFa in the regulation of VCAM-1 expression, being
protective under basal conditions but promoting endothelial
activation in response to diabetes. This study also highlights the
interplay between inflammatory and metabolic abnormalities
leading to retinal endothelial activation in the context of diabetes.
Materials and Methods
Mice
All animals were treated according to the Principles for the Care
and Use of Animals in Ophthalmic and Vision Research approved
by the Association for Research in Vision and Ophthalmology. All
experiments were approved by the Malmo¨/Lund Animal Care and
Use Committee. Female C57BL/6 wild-type (wt) and ApoE2/2
(B6.129P2-Apoetm1UncN11) mice were purchased from Taconic
(Lille Skensved, Denmark) and TNFa2/2 (B6, 129-Tnf tmlGkl) mice
from the Jackson Laboratory (Charles River, Sulzfeld, Germany).
TNFa2/2 and ApoE2/2mice were intercrossed and F7 TNFa2/2
and F10 ApoE2/2/TNFa2/2 progeny were used in the experi-
ments. For the experiments summarized in Figures 3B and 5, and
in Figure S2, all mice were from Jackson Laboratory (strain name
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for ApoE2/2: B6.129P2-Apoetm1Unc/J). For the effects of high fat
diet, normolipidemic FVBN mice were also used. Animals had free
access to tap water and were fed normal chow (R3; Lantma¨nnen,
Kimstad, Sweden) or high fat diet (HFD; R638: 0.15% cholesterol,
21% fat; Lantma¨nnen) as indicated in the text.
Study design
Data from 3 different sets of in vivo experiments are included in
this manuscript. In the first one, we investigated the effects of
diabetes and genotype on VCAM-1 expression, whereas in the
second and third sets, we examined the effects of HFD in
dyslipidemic and normolipidemic mice respectively.
In the first set of experiments, wt, ApoE2/2, TNFa2/2 and
ApoE2/2/TNFa2/2 mice received intraperitoneal injections of
streptozocin (STZ; Sigma-Aldrich, Stockholm, Sweden; 60 mg in
citrate buffer per kg body weight, pH 4.5) or vehicle (citrate buffer)
once a day for 5 days at an age of 22 weeks. Body weight was
measured once a week and animals with .15% weight loss were
excluded from the study (two C57BL/6 wt, one TNFa2/2 and
four ApoE2/2 mice). Blood glucose was measured once a week in
whole venous blood using a One-Touch glucometer (LifeScan
Inc., CA, USA). 8 weeks after the first STZ injection, animals were
anaesthetized with 300 mL intraperitoneal mixture of distilled
water, fentanyl-fluanisone and midazolam (2:1:1), and euthanized
by exsanguination through cardiac puncture. Blood samples were
collected and eyes immediately enucleated. Retinas were carefully
dissected and either used for immunohistochemistry or for mRNA
expression analysis in whole retinas. For immunohistochemistry,
retinas were flattened by four radial cuts, mounted on filter paper
with the vitreous side up, and thereafter fixated in Histochoice at
4uC. For mRNA analysis, retinas were gently peeled off from the
pigment epithelium before frozen on dry ice and stored at 280uC.
The numbers of mice included were 28 wt (16 STZ and 12
vehicle), 29 ApoE2/2 (17 STZ and 12 vehicle), 24 TNFa2/2 (14
STZ and 10 vehicle) and 30 ApoE2/2/TNFa2/2 (15 STZ and 15
vehicle). For mRNA expression in isolated retinal vessels (see real-
time RT-PCR below), additional ApoE2/2 mice (12 STZ and 12
vehicle) were used.
For the effects of HFD, two separate sets of animals were used:
1) 7 wt and 14 ApoE2/2 mice (7 chow and 7 HFD, 1 month on
diet), 13 weeks of age at the start of the experiment and 2) 29
FVBN mice (16 chow and 13 HFD, 1 or 2 months on diet).
Retinas from these mice were used for mRNA expression in
isolated retinal arteries and for immunohistochemistry of whole
mounts. Monitoring of body weight and blood glucose, and
termination of the experiment were performed as explained above.
Extraction of RNA from intact retina
Extraction of total retinal RNA was performed according to a
modified Chomczynski protocol[52] as previously described[53].
Each retina was homogenized on a rotor-stator Polytron (PT1200
Kinematica AG, Littau-Lucerne, Switzerland) in 1 mL of TRI
reagent (Sigma-Aldrich, Stockholm, Sweden) with 5 mL of
Polyacryl carrier (Molecular Research Center, MRC, Cincinnati,
OH, USA). After addition of 100 mL of 1-bromo-3-chloropropane
(BCP, Sigma-Aldrich, Stockholm, Sweden) samples were vortexed
and left for 15 minutes before phases were separated by
centrifugation at 120006g for 15 minutes at 4uC. The aqueous
phase (RNA) was precipitated with 500 mL of isopropanol at
120006g for 10 minutes at 4uC. The pellet was dissolved in 50 mL
of DEPC-H2O supplemented with 60 U of RNasin Plus RNase
Inhibitor (Promega, Madison, USA). Total RNA quantification
was performed on a spectrophotometer (Biophotometer, Eppen-
dorf, Hamburg, Germany), after which samples were stored at
280uC until analysis.
Isolation of retinal vessels and extraction of RNA
Retinal vasculature was selectively isolated from other compo-
nents of the retina using a modified procedure from the one
described by Navaratna[54]. Briefly, retinas were dissected in ice-
cold Ca2+-free physiological saline solution (PSS, containing in
mmol/L: NaCl, 135; KCl, 5,9; MgCl2, 1,2; Hepes, 11,6; glucose
2,0; pH 7,4), incubated in ice-cold sterile water for 1 hour at 4uC
followed by incubation with bovine pancreatic DNase (25 U,
Sigma) for 10 min. Microvascular networks were cleared from
debris by gently pipetting with a wide-bore Pasteur pipette.
Extraction of RNA from isolated vessels was performed using a
slightly modified protocol as that used for whole retinas. Here, an
Omni Tissue Homogenizer (TH International) and 200 mL
(instead of 100 mL) of 1-bromo-3-chloropropane were used;
samples were vortexed and left for 2–3 minutes before separation
of phases. RNA was precipitated with a combination of 500 mL of
isopropanol and 2,5 mg Linear acrylamide (Ambion, Texas, USA)
and left overnight at 280uC. After a new centrifugation at
120006g for 15 minutes at 4uC, the pellet was washed in 75%
ethanol, further centrifuged and dissolved in 13 mL of DEPC-H2O
supplemented with 13 U RiboLock RNase inhibitor (Fermentas
GMBH, St. Leon-Rot, Germany).
Real time RT-PCR
For the total retinal RNA analysis, cDNA was synthesized from
2 mg of RNA using 200 U RevertAid RNase H2 RT (Fermentas,
Helsingborg, Sweden) and 250 ng random hexamer (Amersham
Biosciences, Uppsala, Sweden) primer for two hours at 42uC.
Expression of VCAM-1, ICAM-1, P-selectin, E-selectin, TNFa, IL-
6, IL1b, IFNc, caspase-1 and the internal control cyclophilin B
(Ppib) mRNA levels were analyzed using real-time RT-PCR on a
7900HT system (Applied Biosystems, Stockholm, Sweden). Taq-
Man assays were from Applied Biosystems (assays on demand);
VCAM-1 (Mm01320970_m1), ICAM-1 (Mm00516023_m1),
E-selectin (Mm00441278_m1), P-selectin (Mm00441295_m1),
TNFa (Mm99999068_m1), IL-6 (Mm00446190_m1), IL-1b
(Mm01336189_m1), IFNc (Mm01168134_m1), Caspase 1
(Mm00438023_m1) and Ppib (Mm00478295_m1). For RNA
analysis in isolated retinal vessels, cDNA was synthesized with the
RevertAidTM HMinus M-MuLV Reverse transcriptase (Fermentas
GMBH, St. Leon-Rot, Germany) according to the manufacturer’s
instructions. The Gene expression Assays used were: VCAM-1
(Mm01320970_m1), ICAM-1 (Mm00516023_m1), E-selectin
(Mm00441278_m1) and Ppib (Mm00478295_m1) and GAPDH
(4352339E) as housekeeping controls. The relative quantity of target
genes was calculated using the comparative threshold method
(DDCt) and using Ppib as endogenous control as previously
described[55]. For isolated vessels Genormv. 3.5 software was used
to relate target expression to both endogenous controls, Ppib and
GAPDH.
Confocal immunofluorescence: VCAM-1 detection
Whole mount retinas were cleaned in phosphate-buffered saline
(PBS, pH 7.4; Sigma-Aldrich, Stockholm, Sweden), permeabilized
with 0.2% Triton X-100 in PBS and blocked with 2% bovine
serum albumin (BSA) in PBS for 2 hours. For detection of VCAM-
1 the primary antibody rat anti-mouse CD 106 (#M/K-2;
Chemicon International, Inc., Millipore, Solna, Sweden) was
diluted 1:400 in 2% BSA/PBS and applied overnight at 4uC. The
secondary antibody, Cy5 anti-rat IgG (Jackson ImmunoResearch
Laboratories, Charles River, Sulzfeld, Germany), was diluted
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1:500 and applied for 2 hours at room temperature. For
identification of nuclei, the fluorescent nucleic acid dye SYTOX
Green (Invitrogen, Paisley, UK) 1:3000 was applied for 10
minutes. Whole retinas were mounted on slides (Aqua Polymount
mounting medium, Polysciences, Eppelheim, Germany), exam-
ined at 63X using a Zeiss LSM 5 Pascal laser scanning confocal
microscope. VCAM-1 was detected by monitoring Cy5 fluores-
cence using an excitation wavelength of 633 nm and an emission
wavelength of .650 nm. At least 3 images were taken from each
vessel branch and approximately 80 images were taken on average
per retina. Mean pixel intensity (ranging 0 to 255 grayscale values,
after background subtraction) and vessel diameter were measured
using the Zeiss LSM 5 software. Specificity of immune staining
was confirmed by the absence of fluorescence in arteries incubated
with primary or secondary antibodies alone (Figure S3).
Experiments as well as analysis were performed under blind
conditions.
Total plasma cholesterol, HDL and triglycerides
Total plasma cholesterol and triglycerides were quantified with
colorimetric assays, InfinityTM Cholesterol and InfinityTM
Triglycerides (both from Thermo Scientific, Middletown, VA,
USA) according to the manufacturer’s instructions. HDL levels
were measured after precipitation of Apo-B containing lipopro-
teins using a modified version of a previously described
protocol[56]. Briefly, plasma was diluted 1:4 with PBS and VLDL
and LDL precipitated by adding Dextran Sulphate Na-salt (1 mg/
ml) and MgCl2 (0.09 M), for 1 hour at +4uC. After centrifugation,
HDL cholesterol content was examined in the supernatant.
Absorbance was measured at 492 nm (Tecan Sunrise, program
Magellan). LDL was calculated by the Friedewald equation[57]:
LDL = total cholesterol – [HDL + (Triglycerides 60.20)]. All
triglyceride values were below 4.52 mmol/l, which is the
recommended TG limit for indirect LDL calculations.
sVCAM-1 ELISA
The levels of sVCAM-1 in plasma were assayed using
QuantikineH Mouse sVCAM-1 ELISA kit (R&D Systems,
Abingdon, UK) according to the manufacturer’s instructions.
Absorbance was measured at 450 nm (Tecan Sunrise, program
Magellan) and the lower limit of detection was 0.31 ng/ml.
Statistics
Results are expressed as mean6 SEM unless otherwise stated in
the figure legends. Statistical analysis was performed using SPSS
version 15.0.1 and Graph Pad software (Prism 4.0). Analyses of
distributions were performed before decisions were made to use
parametric tests. Statistical significance was determined using
Student’s t-test, one- or two-way ANOVA as specified in the text,
followed by Bonferroni post hoc tests. Pearson’s test was used for
correlation analyses.
Supporting Information
Figure S1 (A) Confocal immunofluorescence microscopy images
showing merged VCAM-1 (red)- and nuclei (green) fluorescence in
the left panel; single VCAM-1 fluorescence in the middle panel
and single green fluorescence in the right panel. Images are from a
retinal whole-mount from a non-diabetic ApoE2/2 mouse. Note
adjacent VCAM-1 positive and negative vessels (white arrows).
Bars = 50 mm. (B) Summarized calculations from confocal immu-
nofluorescence microscopy data showing percentage of VCAM-1
positive and VCAM-1 negative vessels in retinas from control non-
diabetic and diabetic wt, ApoE2/2, TNFa2/2 and ApoE2/2/
TNFa2/2 mice. The percentage of VCAM-1 positive vessels was
reduced in diabetic animals from wt and ApoE2/2 groups
(*p,0.05 and ***p,0.001, respectively), but unaltered in the
TNFa2/2 genotypes.
Found at: doi:10.1371/journal.pone.0012699.s001 (7.14 MB TIF)
Figure S2 Expression of ICAM-1 and E-selectin mRNA was
studied by real time RT-PCR in normolipidemic FVBN mice.
Expression was not affected by 4 or 8 weeks of HFD (plain and
patterned gray bars, respectively) when compared to mice fed
regular chow diet (white bars). Values are normalized to the
expression of cyclophilin B and GAPDH.
Found at: doi:10.1371/journal.pone.0012699.s002 (1.29 MB TIF)
Figure S3 Negative control: Representative confocal immuno-
fluorescence microscopy image showing absence of red immuno-
fluorescence in vessels incubated with secondary antibody alone
(Cy5 anti-rat IgG). Retinal whole mount was counterstained with
SYTOX green for structure identification. Bars = 50 mm.
Found at: doi:10.1371/journal.pone.0012699.s003 (6.95 MB TIF)
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